Nutritional status and structural brain changes in Alzheimer's disease: The NUDAD project
- PMID: 32793798
- PMCID: PMC7418890
- DOI: 10.1002/dad2.12063
Nutritional status and structural brain changes in Alzheimer's disease: The NUDAD project
Abstract
Introduction: Weight loss is associated with higher mortality and progression of cognitive decline, but its associations with magnetic resonance imaging (MRI) changes related to Alzheimer's disease (AD) are unknown.
Methods: We included 412 patients from the NUDAD project, comprising 129 with AD dementia, 107 with mild cognitive impairment (MCI), and 176 controls. Associations between nutritional status and MRI measures were analyzed using linear regression, adjusted for age, sex, education, cognitive functioning, and cardiovascular risk factors.
Results: Lower body mass index (BMI), fat mass (FM), and fat free mass index were associated with higher medial temporal atrophy (MTA) scores. Lower BMI, FM, and waist circumference were associated with more microbleeds. Stratification by diagnosis showed that the observed associations with microbleeds were only significant in MCI.
Discussion: Lower indicators of nutritional status were associated with more MTA and microbleeds, with largest effect sizes in MCI.
Keywords: body mass index; cerebral atrophy; fat free mass; fat mass; magnetic resonance imaging; malnutrition; microbleeds; mild cognitive impairment; nutritional status; white matter hyperintensities.
© 2020 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Conflict of interest statement
Charlotte E. Teunissen received grants from the European Commission, the Dutch Research Council (ZonMW), Association of Frontotemporal Dementia/Alzheimer's Drug Discovery Foundation, The Weston Brain Institute, Alzheimer Netherlands. Charlotte E. Teunissen has a collaboration contract with ADx Neurosciences, performed contract research or received grants from Probiodrug, Biogen, Esai, Toyama, Janssen prevention center, Boehringer, AxonNeurosciences, Fujirebio, EIP farma, PeopleBio, and Roche. Bart NM van Berckel received research support from ZonMW, AVID radiopharmaceuticals, CTMM, and Janssen Pharmaceuticals. He is a trainer for Piramal and GE. He receives no personal honoraria. Frederik Barkhof is a consultant for Biogen‐Idec, Janssen Alzheimer Immunotherapy, Bayer‐Schering, Merck‐Serono, Roche, Novartis, Genzyme, and Sanofi‐Aventis; has received sponsorship from European Commission–Horizon 2020, National Institute for Health Research–University College London Hospitals Biomedical Research Centre, Scottish Multiple Sclerosis Register, TEVA, Novartis, and Toshiba; and serves on the editorial boards of Radiology, Brain, Neuroradiology, Multiple Sclerosis Journal, and Neurology. Philip Scheltens has received consultancy/speaker fees from Lilly, GE Healthcare, Novartis, Sanofi, Nutricia, Probiodrug, Biogen, Roche, Avraham, and EIP Pharma. PS has acquired grant support from GE Healthcare, Danone Research, Piramal, and MERCK. All funding was paid to the institution. Wiesje M van der Flier received grants from ZonMW, the Food cognition and behavior program of The Dutch Research Council (NWO‐FCB), The EU Joint Programme–Neurodegenerative Disease Research (EU‐JPND), Alzheimer Nederland, Health‐Holland, Topsector Life Sciences & Health, Biogen MA Inc, Boehringer Ingelheim, Life Molecular Imaging, AVID Radiopharmaceuticals, Roche BV, Combinostics, Janssen Stellar, Gieskes Strijbis fonds, and Stichting Equilibrio. Wiesje M van der Flier has performed contract research for Biogen MA Inc and Boehringer Ingelheim and has been an invited speaker at Boehringer Ingelheim and Biogen MA Inc. All funding was paid to the institution. Barbara JH Verhaar, Francisca A de Leeuw, Astrid S Doorduijn, Jay LP Fieldhouse, Ondine van de Rest, Marjolein Visser, Marian AE de van der Schueren, Maartje I Kester, and Majon Muller report no disclosures.
Figures


References
-
- Knopman DS, Edland SD, Cha RH, Petersen RC, Rocca WA. Incident dementia in women is preceded by weight loss by at least a decade. Neurology. 2007;69:739‐746. - PubMed
-
- Johnson DK, Wilkins CH, Morris JC. Accelerated weight loss may precede diagnosis in Alzheimer disease. Arch Neurol. 2006;63:1312‐1317. - PubMed
-
- Guerin O, Soto ME, Brocker P, Robert PH, Benoit M, Vellas B. Nutritional status assessment during Alzheimer's disease: results after one year (the REAL French Study Group). J Nutr Health Aging. 2005;9:81‐84. - PubMed
-
- Andrieu S, Reynish W, Nourhashemi F, et al. Nutritional risk factors for institutional placement in Alzheimer's disease after one year follow‐up. J Nutr Health Aging. 2001;5:113‐117. - PubMed
LinkOut - more resources
Full Text Sources